MK2870-015: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Merck
To compare MK-2870 to TPC
with respect to OS.To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR. To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed by BICR.
Enrollment Form
This study is currently enrolling.